<- Go Home
Ainos, Inc.
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women’s health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.
Market Cap
$6.0M
Volume
816.5K
Cash and Equivalents
$5.2M
EBITDA
-$9.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$143.3K
Profit Margin
352.79%
52 Week High
$4.29
52 Week Low
$0.40
Dividend
N/A
Price / Book Value
0.33
Price / Earnings
-0.19
Price / Tangible Book Value
-0.87
Enterprise Value
$13.1M
Enterprise Value / EBITDA
-1.33
Operating Income
-$14.6M
Return on Equity
70.60%
Return on Assets
-28.02
Cash and Short Term Investments
$5.2M
Debt
$12.3M
Equity
$18.0M
Revenue
$40.6K
Unlevered FCF
$755.9K
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium